Developmental loss and resistance to MPTP toxicity of dopaminergic neurones in substantia nigra pars compacta of γ‐synuclein, α‐synuclein and double α/γ‐synuclein null mutant mice

The growing body of evidence suggests that intermediate products of α‐synuclein aggregation cause death of sensitive populations of neurones, particularly dopaminergic neurones, which is a critical event in the development of Parkinson's disease and other synucleinopathies. The role of two other members of the family, β‐synuclein and γ‐synuclein, in neurodegeneration is less understood. We studied the effect of inactivation of γ‐synuclein gene on mouse midbrain dopaminergic neurones. Reduced number of dopaminergic neurones was found in substantia nigra pars compacta (SNpc) but not in ventral tegmental area (VTA) of early post‐natal and adult γ‐synuclein null mutant mice. Similar reductions were revealed in α‐synuclein and double α‐synuclein/γ‐synuclein null mutant animals. However, in none of these mutants did this lead to significant changes of striatal dopamine or dopamine metabolite levels and motor dysfunction. In all three studied types of null mutants, dopaminergic neurones of SNpc were resistant to methyl‐phenyl‐tetrahydropyridine (MPTP) toxicity. We propose that both synucleins are important for effective survival of SNpc neurones during critical period of development but, in the absence of these proteins, permanent activation of compensatory mechanisms allow many neurones to survive and become resistant to certain toxic insults.

[1]  R. Crowther,et al.  α-Synuclein in filamentous inclusions of Lewy bodies from Parkinson’s disease and dementia with Lewy bodies , 1998 .

[2]  Virginia M. Y. Lee,et al.  Oxidative post‐translational modifications of α‐synuclein in the 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine (MPTP) mouse model of Parkinson's disease , 2001, Journal of neurochemistry.

[3]  Makoto Hashimoto,et al.  Development of a new treatment for alzheimer’s disease and parkinson’s disease using anti-aggregatory β-synuclein-derived peptides , 2002, Journal of Molecular Neuroscience.

[4]  P. Brundin,et al.  Effect of Mutant α-Synuclein on Dopamine Homeostasis in a New Human Mesencephalic Cell Line* , 2002, The Journal of Biological Chemistry.

[5]  V. P. Whittaker,et al.  The Synaptic Vesicle , 1984 .

[6]  Junying Yuan,et al.  Releasing the nerve cell killers , 2002, Nature Medicine.

[7]  A. Björklund,et al.  Nigrostriatal α-synucleinopathy induced by viral vector-mediated overexpression of human α-synuclein: A new primate model of Parkinson's disease , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[8]  A. Dehejia,et al.  Identification, localization and characterization of the human γ-synuclein gene , 1998, Human Genetics.

[9]  P. Lansbury,et al.  Annular alpha-synuclein protofibrils are produced when spherical protofibrils are incubated in solution or bound to brain-derived membranes. , 2002, Biochemistry.

[10]  M. Abercrombie Estimation of nuclear population from microtome sections , 1946, The Anatomical record.

[11]  Sebastian Doniach,et al.  Biophysical Properties of the Synucleins and Their Propensities to Fibrillate , 2002, The Journal of Biological Chemistry.

[12]  Heidi Phillips,et al.  Mice Lacking α-Synuclein Display Functional Deficits in the Nigrostriatal Dopamine System , 2000, Neuron.

[13]  Seung-Jae Lee α-Synuclein Aggregation: A Link Between Mitochondrial Defects and Parkinson's Disease? , 2003 .

[14]  C. Bruce,et al.  Chaperone Suppression of a-Synuclein Toxicity in a Drosophila Model for Parkinson's Disease , 2002 .

[15]  Howard J. Federoff,et al.  Behavioral and Neurochemical Effects of Wild-Type and Mutated Human α-Synuclein in Transgenic Mice , 2002, Experimental Neurology.

[16]  A. Björklund,et al.  Parkinson-Like Neurodegeneration Induced by Targeted Overexpression of α-Synuclein in the Nigrostriatal System , 2002, The Journal of Neuroscience.

[17]  M. Pericak-Vance,et al.  Absence of Mutation in the β- and γ-Synuclein Genes in Familial Autosomal Dominant Parkinson's Disease , 1998 .

[18]  R. Burke Postnatal Developmental Programmed Cell Death in Dopamine Neurons , 2003, Annals of the New York Academy of Sciences.

[19]  K. Prasad,et al.  Overexpression of human α-synuclein causes dopamine neuron death in rat primary culture and immortalized mesencephalon-derived cells , 2000, Brain Research.

[20]  Johannes Schwarz,et al.  Expression of mutant &agr;-synucleins enhances dopamine transporter-mediated MPP+ toxicity in vitro , 2002, Neuroreport.

[21]  J. Trojanowski,et al.  Axon pathology in Parkinson ’ s disease and Lewy body dementia hippocampus contains a-, b-, and g-synuclein , 1999 .

[22]  P. Lansbury,et al.  Zeroing in on the pathogenic form of alpha-synuclein and its mechanism of neurotoxicity in Parkinson's disease. , 2003, Biochemistry.

[23]  P. Lansbury,et al.  Vesicle permeabilization by protofibrillar alpha-synuclein is sensitive to Parkinson's disease-linked mutations and occurs by a pore-like mechanism. , 2002, Biochemistry.

[24]  Robert Burke,et al.  Resistance of α-synuclein null mice to the parkinsonian neurotoxin MPTP , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[25]  Hitoshi Takahashi,et al.  α-Synuclein immunoreactivity in glial cytoplasmic inclusions in multiple system atrophy , 1998, Neuroscience Letters.

[26]  Jie Li,et al.  The Association of α-Synuclein with Membranes Affects Bilayer Structure, Stability, and Fibril Formation* , 2003, Journal of Biological Chemistry.

[27]  J. Powell,et al.  Mutations in the gene encoding human persyn are not associated with amyotrophic lateral sclerosis or familial Parkinson's disease , 1999, Neuroscience Letters.

[28]  A. Davies,et al.  Induction of neuronal death by α‐synuclein , 2000, The European journal of neuroscience.

[29]  R. Blakely,et al.  Dopaminergic neuronal loss and motor deficits in Caenorhabditis elegans overexpressing human α‐synuclein , 2003, Journal of neurochemistry.

[30]  Robert L. Nussbaum,et al.  Mutation in the α-Synuclein Gene Identified in Families with Parkinson's Disease , 1997 .

[31]  M. Citron,et al.  a-Synuclein Fibrillogenesis Is Nucleation-dependent IMPLICATIONS FOR THE PATHOGENESIS OF PARKINSON 9 S DISEASE , 1999 .

[32]  J. Trojanowski,et al.  Antibodies to α‐synuclein detect Lewy bodies in many Down's syndrome brains with Alzheimer's disease , 1999, Annals of neurology.

[33]  F. Checler,et al.  Alpha-synuclein lowers p53-dependent apoptotic response of neuronal cells. Abolishment by 6-hydroxydopamine and implication for Parkinson's disease. , 2002, The Journal of biological chemistry.

[34]  R. Krüger,et al.  Evaluation of the γ-synuclein gene in German Parkinson's disease patients , 2001, Neuroscience Letters.

[35]  Kenji Ikeda,et al.  Argyrophilic glial inclusions in the midbrain of patients with Parkinson's disease and diffuse Lewy body disease are immunopositive for NACP/α-synuclein , 1999, Neuroscience Letters.

[36]  Peter T. Lansbury,et al.  Accelerated in vitro fibril formation by a mutant α-synuclein linked to early-onset Parkinson disease , 1998, Nature Medicine.

[37]  Nigel J. Cairns,et al.  Filamentous α-synuclein inclusions link multiple system atrophy with Parkinson's disease and dementia with Lewy bodies , 1998, Neuroscience Letters.

[38]  L. Petrucelli,et al.  α-Synuclein Shares Physical and Functional Homology with 14-3-3 Proteins , 1999, The Journal of Neuroscience.

[39]  Hitoshi Takahashi,et al.  Pick's disease: α- and β-synuclein-immunoreactive Pick bodies in the dentate gyrus , 2002, Acta Neuropathologica.

[40]  W. Bender,et al.  A Drosophila model of Parkinson's disease , 2000, Nature.

[41]  M. Citron,et al.  Both Familial Parkinson’s Disease Mutations Accelerate α-Synuclein Aggregation* , 1999, The Journal of Biological Chemistry.

[42]  J. Schaack,et al.  Overexpression of human α-synuclein causes dopamine neuron death in primary human mesencephalic culture , 2002, Brain Research.

[43]  R. Crowther,et al.  a-Synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with Lewy bodies (ubiquitinysarkosyl-insoluble filamentsyimmunoelectron microscopy) , 1998 .

[44]  J. Hardy,et al.  Pathways to primary neurodegenerative disease. , 1999, Neurologia.

[45]  Chaperones Take Flight , 2002, Science.

[46]  E. Masliah,et al.  C-terminal α-synuclein immunoreactivity in structures other than Lewy bodies in neurodegenerative disorders , 2000, Acta Neuropathologica.

[47]  Vladimir N. Uversky,et al.  Amino acid determinants of α‐synuclein aggregation: putting together pieces of the puzzle , 2002 .

[48]  S. Helfand Neurobiology. Chaperones take flight. , 2002, Science.

[49]  Patrik Brundin,et al.  Pathogenesis of parkinson's disease: dopamine, vesicles and α-synuclein , 2002, Nature Reviews Neuroscience.

[50]  A. Davies,et al.  Developmentally regulated expression of persyn, a member of the synuclein family, in skin. , 1999, Experimental cell research.

[51]  E. Masliah,et al.  α-Synuclein Promotes Mitochondrial Deficit and Oxidative Stress , 2000 .

[52]  E. Masliah,et al.  β-Synuclein Displays an Antiapoptotic p53-dependent Phenotype and Protects Neurons from 6-Hydroxydopamine-induced Caspase 3 Activation , 2003, Journal of Biological Chemistry.

[53]  A. Davies,et al.  Persyn, a Member of the Synuclein Family, Has a Distinct Pattern of Expression in the Developing Nervous System , 1998, The Journal of Neuroscience.

[54]  Richard Paylor,et al.  Synaptic Vesicle Depletion Correlates with Attenuated Synaptic Responses to Prolonged Repetitive Stimulation in Mice Lacking α-Synuclein , 2002, The Journal of Neuroscience.

[55]  Peter T Lansbury,et al.  Beta-synuclein inhibits formation of alpha-synuclein protofibrils: a possible therapeutic strategy against Parkinson's disease. , 2003, Biochemistry.

[56]  P. Lockhart,et al.  Parkin Protects against the Toxicity Associated with Mutant α-Synuclein Proteasome Dysfunction Selectively Affects Catecholaminergic Neurons , 2002, Neuron.

[57]  N. Bonini Chaperoning brain degeneration , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[58]  M. Citron,et al.  α-Synuclein Fibrillogenesis Is Nucleation-dependent , 1999, The Journal of Biological Chemistry.

[59]  V. Buchman,et al.  Part II: α-synuclein and its molecular pathophysiological role in neurodegenerative disease , 2003, Neuropharmacology.

[60]  B. Hyman,et al.  Nigral and Cortical Lewy Bodies and Dystrophic Nigral Neurites in Parkinson's Disease and Cortical Lewy Body Disease Contain α-synuclein Immunoreactivity , 1998, Journal of neuropathology and experimental neurology.

[61]  A. Davies,et al.  Neurons Expressing the Highest Levels of γ-Synuclein Are Unaffected by Targeted Inactivation of the Gene , 2003, Molecular and Cellular Biology.

[62]  A. Dehejia,et al.  Alpha synuclein is present in Lewy bodies in sporadic Parkinson's disease , 1998, Molecular Psychiatry.

[63]  L. Serpell,et al.  Fiber diffraction of synthetic alpha-synuclein filaments shows amyloid-like cross-beta conformation. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[64]  P. Lansbury,et al.  Vesicle permeabilization by protofibrillar alpha-synuclein: implications for the pathogenesis and treatment of Parkinson's disease. , 2001, Biochemistry.

[65]  T. Sherer,et al.  Mechanistic Approaches to Parkinson's Disease Pathogenesis , 2002, Brain pathology.

[66]  M. Citron,et al.  alpha-synuclein fibrillogenesis is nucleation-dependent. Implications for the pathogenesis of Parkinson's disease. , 1999, The Journal of biological chemistry.

[67]  P. Lansbury,et al.  Alpha-synuclein, especially the Parkinson's disease-associated mutants, forms pore-like annular and tubular protofibrils. , 2002, Journal of molecular biology.

[68]  Smita Patel,et al.  Golgi Fragmentation Occurs in the Cells with Prefibrillar α-Synuclein Aggregates and Precedes the Formation of Fibrillar Inclusion* , 2002, The Journal of Biological Chemistry.

[69]  A. Sidhu,et al.  Differential cytotoxicity of dopamine and H2O2 in a human neuroblastoma divided cell line transfected with α-synuclein and its familial Parkinson's disease-linked mutants , 2003, Neuroscience Letters.

[70]  S. Totterdell,et al.  Lysosomal malfunction accompanies alpha-synuclein aggregation in a progressive mouse model of Parkinson’s disease , 2002, Brain Research.

[71]  INTERNATIONAL SOCIETY FOR NEUROCHEMISTRY , 1976 .

[72]  Makoto Hashimoto,et al.  β-Synuclein Inhibits α-Synuclein Aggregation A Possible Role as an Anti-Parkinsonian Factor , 2001, Neuron.

[73]  M. Vila,et al.  α‐Synuclein Up‐Regulation in Substantia Nigra Dopaminergic Neurons Following Administration of the Parkinsonian Toxin MPTP , 2000, Journal of neurochemistry.

[74]  Z. Wang,et al.  Parkinsonism proteolysis and proteasomes , 2002, Cell Death and Differentiation.

[75]  D. Latchman,et al.  Modulation of cell death by α-synuclein is stimulus-dependent in mammalian cells , 2003, Neuroscience Letters.

[76]  John Q. Trojanowski,et al.  Chaperone Suppression of α-Synuclein Toxicity in a Drosophila Model for Parkinson's Disease , 2001, Science.

[77]  J. Feldon,et al.  Overexpression of Parkinson's disease-associated alpha-synucleinA53T by recombinant adeno-associated virus in mice does not increase the vulnerability of dopaminergic neurons to MPTP. , 2002, Journal of neurobiology.

[78]  J. Trojanowski,et al.  The Expression of α-, β-, and γ-Synucleins in Olfactory Mucosa from Patients with and without Neurodegenerative Diseases , 1999, Experimental Neurology.

[79]  MoonHee Lee,et al.  Effect of the overexpression of wild‐type or mutant α‐synuclein on cell susceptibility to insult , 2001 .

[80]  G. Petzinger,et al.  The parkinsonian toxin 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine (MPTP): a technical review of its utility and safety , 2001, Journal of neurochemistry.

[81]  J Q Trojanowski,et al.  Axon pathology in Parkinson's disease and Lewy body dementia hippocampus contains alpha-, beta-, and gamma-synuclein. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[82]  L. Greene,et al.  Expression of A53T Mutant But Not Wild-Type α-Synuclein in PC12 Cells Induces Alterations of the Ubiquitin-Dependent Degradation System, Loss of Dopamine Release, and Autophagic Cell Death , 2001, The Journal of Neuroscience.

[83]  J. Trojanowski,et al.  Neurodegeneration with Brain Iron Accumulation, Type 1 Is Characterized by α-, β-, and γ-Synuclein Neuropathology , 2000 .

[84]  Wenzhen Duan,et al.  Neuroprotective and neurorestorative signal transduction mechanisms in brain aging: modification by genes, diet and behavior , 2002, Neurobiology of Aging.

[85]  R. Krüger,et al.  Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. , 1998, Nature genetics.

[86]  A. Destée,et al.  No pathogenic mutations in the persyn gene in Parkinson's disease , 1999, Neuroscience Letters.

[87]  S. Kish,et al.  In situ detection of apoptotic nuclei in the substantia nigra compacta of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated mice using terminal deoxynucleotidyl transferase labelling and acridine orange staining , 1997, Neuroscience.

[88]  P. Aebischer,et al.  α-Synucleinopathy and selective dopaminergic neuron loss in a rat lentiviral-based model of Parkinson's disease , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[89]  M. Cookson Pathways to Parkinsonism , 2003, Neuron.

[90]  J. Schulz,et al.  Parkinson's disease: one biochemical pathway to fit all genes? , 2002, Trends in molecular medicine.

[91]  C. Stichel,et al.  The mouse MPTP model: gene expression changes in dopaminergic neurons , 2003, The European journal of neuroscience.

[92]  L. Serpell,et al.  Fiber diffraction of synthetic a-synuclein filaments shows amyloid-like cross-b conformation , 2000 .

[93]  Olaf Riess,et al.  AlaSOPro mutation in the gene encoding α-synuclein in Parkinson's disease , 1998, Nature Genetics.

[94]  T. Südhof,et al.  Role of α-synuclein in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in mice , 2003, Neuroscience.

[95]  P. Lansbury,et al.  Fibrils formed in vitro from alpha-synuclein and two mutant forms linked to Parkinson's disease are typical amyloid. , 2000, Biochemistry.

[96]  J B Schulz,et al.  Sensitivity to MPTP is not increased in Parkinson's disease‐associated mutant α‐synuclein transgenic mice , 2001, Journal of neurochemistry.

[97]  Bruce A. Yankner,et al.  Dopamine-dependent neurotoxicity of α-synuclein: A mechanism for selective neurodegeneration in Parkinson disease , 2002, Nature Medicine.

[98]  A. Destée,et al.  No pathogenic mutations in the β-synuclein gene in Parkinson's disease , 1999, Neuroscience Letters.

[99]  Philippe Hantraye,et al.  MPTP induces alpha‐synuclein aggregation in the substantia nigra of baboons , 2000, Neuroreport.

[100]  M. L. Schmidt,et al.  α-Synuclein in Lewy bodies , 1997, Nature.